Literature DB >> 23630964

Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion.

Chaoqun Yao1, Upasna Gaur Dixit, Jason H Barker, Lynn M Teesch, Laurie Love-Homan, John E Donelson, Mary E Wilson.   

Abstract

The infectious metacyclic promastigotes of Leishmania protozoa establish infection in a mammalian host after they are deposited into the dermis by a sand fly vector. Several Leishmania virulence factors promote infection, including the glycosylphosphatidylinositol membrane-anchored major surface protease (MSP). Metacyclic Leishmania infantum chagasi promastigotes were treated with methyl-beta-cyclodextrin (MβCD), a sterol-chelating reagent, causing a 3-fold reduction in total cellular sterols as well as enhancing MSP release without affecting parasite viability in vitro. MβCD-treated promastigotes were more susceptible to complement-mediated lysis than untreated controls and reduced the parasite load 3-fold when inoculated into BALB/c mice. Paradoxically, MβCD-treated promastigotes caused a higher initial in vitro infection rate in human or murine macrophages than untreated controls, although their intracellular multiplication was hindered upon infection establishment. There was a corresponding larger amount of covalently bound C3b than iC3b on the parasite surfaces of MβCD-treated promastigotes exposed to healthy human serum in vitro, as well as loss of MSP, a protease that enhances C3b cleavage to iC3b. Mass spectrometry showed that MβCD promotes the release of proteins into the extracellular medium, including both MSP and MSP-like protein (MLP), from virulent metacyclic promastigotes. These data support the hypothesis that plasma membrane sterols are important for the virulence of Leishmania protozoa at least in part through retention of membrane virulence proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23630964      PMCID: PMC3697599          DOI: 10.1128/IAI.00214-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  70 in total

1.  Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana.

Authors:  Julio A Urbina; Juan Luis Concepcion; Salomé Rangel; Gonzalo Visbal; Renee Lira
Journal:  Mol Biochem Parasitol       Date:  2002 Nov-Dec       Impact factor: 1.759

2.  Monoclonal antibody affinity purification of a Leishmania membrane glycoprotein and its inhibition of leishmania-macrophage binding.

Authors:  C S Chang; K P Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

Review 3.  Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites.

Authors:  J A Urbina
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

4.  Expression of the major surface glycoprotein of Leishmania donovani chagasi in virulent and attenuated promastigotes.

Authors:  M E Wilson; K K Hardin; J E Donelson
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

5.  Leishmania amazonensis promastigotes evade complement killing by interfering with the late steps of the cascade.

Authors:  A C Nunes; F R Almeida-Campos; M F Horta; F J Ramalho-Pinto
Journal:  Parasitology       Date:  1997-12       Impact factor: 3.234

6.  A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation.

Authors:  G F Späth; S M Beverley
Journal:  Exp Parasitol       Date:  2001-10       Impact factor: 2.011

7.  Biosynthesis of the major surface protease GP63 of Leishmania chagasi.

Authors:  Chaoqun Yao; Kevin G Leidal; Andrew Brittingham; Deirdre E Tarr; John E Donelson; Mary E Wilson
Journal:  Mol Biochem Parasitol       Date:  2002-04-30       Impact factor: 1.759

Review 8.  Conservation of eukaryotic sterol homeostasis: new insights from studies in budding yeast.

Authors:  S L Sturley
Journal:  Biochim Biophys Acta       Date:  2000-12-15

9.  Use of cyclodextrins for manipulating cellular cholesterol content.

Authors:  A E Christian; M P Haynes; M C Phillips; G H Rothblat
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

10.  Effect of ketoconazole on lethal action of amphotericin B on Leishmania mexicana promastigotes.

Authors:  H Ramos; M Saint-Pierre-Chazalet; J Bolard; B E Cohen
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more
  6 in total

1.  Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response.

Authors:  Edubiel A Alpizar-Sosa; Nur Raihana Binti Ithnin; Wenbin Wei; Andrew W Pountain; Stefan K Weidt; Anne M Donachie; Ryan Ritchie; Emily A Dickie; Richard J S Burchmore; Paul W Denny; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2022-09-28

Review 2.  Innate immunity against Leishmania infections.

Authors:  Prajwal Gurung; Thirumala-Devi Kanneganti
Journal:  Cell Microbiol       Date:  2015-08-11       Impact factor: 3.715

Review 3.  Deception and manipulation: the arms of leishmania, a successful parasite.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Nuno Santarém; Joana Maciel; Vasco Rodrigues; Anabela Cordeiro da Silva
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

4.  Attenuation and Production of the Amphotericin B-Resistant Leishmania tropica Strain.

Authors:  Imran Khan; Momin Khan; Muhammad Naveed Umar; Deog-Hwan Oh
Journal:  Jundishapur J Microbiol       Date:  2016-05-14       Impact factor: 0.747

5.  Extracellular release of virulence factor major surface protease via exosomes in Leishmania infantum promastigotes.

Authors:  Skye Marshall; Patrick H Kelly; Brajesh K Singh; R Marshall Pope; Peter Kim; Bayan Zhanbolat; Mary E Wilson; Chaoqun Yao
Journal:  Parasit Vectors       Date:  2018-06-19       Impact factor: 3.876

6.  Dynamics of sterol synthesis during development of Leishmania spp. parasites to their virulent form.

Authors:  Chaoqun Yao; Mary E Wilson
Journal:  Parasit Vectors       Date:  2016-04-12       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.